Daily Briefing
What the Culture's Talking About
December 22, 2025 • 5 minutes • Hosted by Victoria
Today's Briefing
Episode #122
About This Episode
Who's reinvesting the bag? We got TDE raising millions, Charlamagne's historic $200M deal, and artists giving back to the blocks that built them. Get inspired.
Today's Highlights:
Related Articles:
TDE Holiday Charity Concert And Celebration Attracts Over 8K, Raises $2M As Kendrick Lamar, SZA And More Come Out
Hip-hop label Top Dawg Entertainment brought together some of the biggest names in music during its annual holiday concert and attracted more than 8,000 attendees.
What To Know About Charlamagne Tha God’s $200M Deal With iHeartMedia
Charlamagne Tha God has secured a five-year, $200 million deal with iHeartMedia.
New Orleans Artist Jay McKay Takes His Art To The Streets And Playgrounds That Raised Him With Latest Exhibit
The city of New Orleans means everything to native Jarrad “Jay” McKay, and the artist is declaring his love through his exhibition, “Let The Children Play.
Topics:
Share This Episode
More Episodes
Blavity Daily Briefing
Tap in as we break down a major win for our health. Learn how the new Sac-TMT therapy could transform care for Black women fighting endometrial cancer.
Blavity Daily Briefing
Family, protect your health and your bag. We break down the FDA's Ozempic vision warning and how to outsmart rising ACA healthcare premiums. Tap in!
Blavity Daily Briefing
Family, our care is on the line. We break down the Texas Planned Parenthood Medicaid battle and the DOJ's latest move. See how this impacts our folks.
Blavity Daily Briefing
Historic Black political wins shake up Texas and Mississippi. Plus, we break down surprise medical bills and game-changing health tech. Tap in!
Blavity Daily Briefing
Black women demand their political receipts, while Ole Miss faces accountability. Plus, the real tea on oxytocin doping. Tap in, family!
Blavity Daily Briefing
Black mayors drop gems at AFROTECH™ on life after the midterms. Plus, real talk on cancer caregiving and the truth behind viral 'Ozempic' supplement hype.